MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/gme.0000000000002278

Медицинская библиотека · Menopause (New York, N.Y.) · 2023

Cardiometabolic outcomes in Kronos Early Estrogen Prevention Study continuation: 14-year follow-up of a hormone therapy trial.

Kantarci Kejal, Tosakulwong Nirubol, Lesnick Timothy G, Kara Firat, Kendall-Thomas June, Kapoor Ekta, Fields Julie A, James Taryn T, Lobo Rogerio A, Manson JoAnn E, Pal Lubna, Hammers Dustin B, Malek-Ahmadi Michael, Cedars Marcelle I, Naftolin Frederick N, Santoro Nanette, Miller Virginia M, Harman Sherman M, Dowling N Maritza, Gleason Carey E

СтатьяПеревод в очереди

Аннотация

OBJECTIVE

This study aimed to determine long-term cardiometabolic effects of hormone therapies initiated within 3 years of onset of menopause after a 14-year follow-up study of participants of the Kronos Early Estrogen Prevention Study (KEEPS).

METHODS

KEEPS was a multisite clinical trial that recruited recently menopausal women with good cardiovascular health for randomization to oral conjugated equine estrogens (Premarin, 0.45 mg/d) or transdermal 17β-estradiol (Climara, 50 μg/d) both with micronized progesterone (Prometrium, 200 mg/d) for 12 d/mo, or placebo pills and patch for 4 years. KEEPS continuation recontacted KEEPS participants 14 years after randomization and 10 years after the completion of the 4-year clinical trial to attend in-person clinic visits.

RESULTS

Participants of KEEPS continuation (n = 299 of the 727 KEEPS participants; 41%) had an average age of 67 years (range, 58-73 y). Measurements of systolic and diastolic blood pressures, waist-to-hip ratio, fasting levels of glucose, insulin, lipid profiles, and homeostasis model assessment of insulin resistance were not different among the treatment groups at either KEEPS baseline or at KEEPS continuation visits, or for change between these two visits. The frequency of self-reported diabetes ( P = 0.007) and use of diabetes medications was higher in the placebo than the oral conjugated equine estrogens ( P = 0.045) or transdermal 17β-estradiol ( P = 0.02) groups, but these differences were not supported by the laboratory measurements of glycemia or insulin resistance.

CONCLUSIONS

There was no evidence of cardiovascular and/or metabolic benefits or adverse effects associated with 4 years use of oral or transdermal forms of hormone therapy by recently menopausal women with good cardiovascular health after 10 years.

Для цитирования: Kantarci Kejal, Tosakulwong Nirubol, Lesnick Timothy G, Kara Firat, Kendall-Thomas June, Kapoor Ekta, Fields Julie A, James Taryn T, Lobo Rogerio A, Manson JoAnn E, Pal Lubna, Hammers Dustin B, Malek-Ahmadi Michael, Cedars Marcelle I, Naftolin Frederick N, Santoro Nanette, Miller Virginia M, Harman Sherman M, Dowling N Maritza, Gleason Carey E. Cardiometabolic outcomes in Kronos Early Estrogen Prevention Study continuation: 14-year follow-up of a hormone therapy trial.. Menopause (New York, N.Y.). 2023. DOI: 10.1097/gme.0000000000002278.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.